

# Executive update to the Board

March 2026

# Executive Summary

- This paper provides an update on NICE's performance – including recent notable guidance. **The Board is asked to agree the attached Integrated Performance Review (IPR) report.**
- Since our last meeting, we have published several notable pieces of guidance, providing access to innovative treatments. Examples include:
  - ✓ **New type 2 diabetes guidance could save thousands of lives.** The new guidance will support millions of patients to access SGLT-2 inhibitors ('flozins') much earlier in their treatment pathway, preventing thousands of heart attacks, strokes and cases of kidney failure.
  - ✓ We recommended a breakthrough combination treatment that offers new hope to the nearly 12,000 people in England living with lupus nephritis. Obinutuzumab **significantly improves quality of life**, helping to restore normal kidney function.
  - ✓ Thousands of people living with multiple sclerosis (MS) will benefit from **greater treatment choice** following our recommendation of natalizumab (originator and biosimilar versions). This recommendation reflects our continued work to **support the adoption of biosimilar medicines** to drive **better outcomes for patients and better value for the NHS.**
  - ✓ Following NICE recommendation of bevacizumab biosimilars, thousands more people with advanced bowel cancer will benefit from **life-extending treatment.** We were able to review the biosimilars under NICE's **whole lifecycle approach.**
  - ✓ We recommended an online programme, Overcoming Bulimia Online, for eating disorders, which affect 1.25 million people in the UK. As adults with eating disorders experience long waits for care, the programme will be crucial in giving people **immediate access to proven therapy.**
  - ✓ We published draft guidance recommending eight digital platforms for personalised asthma action plans. Asthma affects 5.4 million people in the UK, especially those from deprived areas. Our recommendation for these digital platforms to be used in the NHS has the potential to **empower patients and reduce health inequalities.**
- Regarding our recent performance, we are on track to:
  - ✓ Meet or exceed annual targets for 72% of our key performance indicators (KPIs).
  - ✓ Achieve the key objectives for our three strategic projects (National HealthTech access programme, whole lifecycle approach, and NICE/MHRA alignment), and meet 93% of the key milestones across all eleven priority projects outlined in our 2025/26 business plan.